Incidence patterns of childhood non-Wilms renal tumors: Comparing data of the Nationwide Registry of Childhood Hematological Malignancies and Solid Tumors (NARECHEM-ST), Greece,and the Surveillance,Epidemiology, and End Results Program (SEER), USA |
| |
| Affiliation: | 1. Department of Maternal-Child and Urological Sciences, Sapienza Rome University, Policlinico Umberto I Hospital, Rome, Italy;2. Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada;3. Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany;4. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany;5. Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy;6. Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy;7. Department of Urology University of Verona, Verona, Italy;8. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria;9. Department of Urology, University of Texas Southwestern, Dallas, TX;10. Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic;11. Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia;12. Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan;13. Department of Urology, Weill Cornell Medical College, New York, NY;1. Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada;2. Urology Unit, Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Italy;3. Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany;4. Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IBCAS San Raffaele Scientific Institute, Milan, Italy;5. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany;6. Department of Urology, Bichat-Claude Bernard Hospital Paris Descartes University, Paris, France;7. Urology Unit, Department of Medicine and surgery “Scuola Medica Salernitana”, University of Salerno, Salerno, Italy;8. Department of Urology, European Institute of Oncology (IEO), IRCCS, Milan, Italy;9. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria;10. Departments of Urology, Weill Cornell Medical College, New York, NY;11. Department of Urology, University of Texas Southwestern, Dallas, TX;12. Department of Urology, Second Faculty of Medicine, Charles University, Prag, Czech Republic;13. Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia;14. Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan;1. Department of Maternal-Child and Urological Sciences, Sapienza University Rome, Policlinico Umberto I Hospital, Rome, Italy;2. Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada;3. Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy;4. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany;5. Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany;6. Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy;7. Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany;8. Departments of Urology, Weill Cornell Medical College, New York, New York, USA;9. Department of Urology, University of Texas Southwestern, Dallas, Texas, USA;10. Department of Urology, Second Faculty of Medicine, Charles University, Prag, Czech Republic;11. Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia;12. Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan;13. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria |
| |
| Abstract: | BackgroundWe used, for the first time, data registered in the Nationwide Registry for Childhood Hematological Malignancies and Solid Tumors (NARECHEM-ST)-Greece to estimate incidence/time trends of the rare childhood (0–14 years) non-Wilms tumors (non-WT), and compared the results of malignant non-WT to those from the Surveillance, Epidemiology, and End Results Program (SEER)-USA.MethodsFifty-five cases (n = 33 malignant-only) were extracted from NARECHEM-ST (2001–2020) and 332 malignant cases from SEER (1990–2017). To allow between-country comparisons, age-standardized incidence rates (AIR) of malignant-only non-WT were calculated, and temporal trends were evaluated using Poisson and joinpoint regressions.ResultsIn NARECHEM-ST, malignant and non-malignant non-WT accounted for 22.6% of all renal tumors. Among malignant tumors, the AIR was 1.0/106 children in Greece, similar to that calculated for SEER, USA (AIR=0.9/106). The proportion of infant malignant and non-malignant non-WT was 27% (20% before 6 months) in NARECHEM-ST. Most common non-WT in Greece were congenital mesoblastic nephromas (CMN) diagnosed mainly in infancy (CIR=7.2/106). The proportion of infant malignant non-WT was 20% in SEER (AIRinfancy=2.5/106), mainly attributed to rhabdoid tumors (CIR=1.6/106). The male-to-female (M:F) ratio of malignant non-WT was 0.9 in NARECHEM-ST vs. 1.2 in SEER, whereas boys outnumbered girls with clear cell sarcoma in NARECHEM-ST (M:F=4.0). Lastly, significantly increasing trends in incidence rates were noted in NARECHEM-ST [+ 6.8%, 95% confidence intervals (CI): 0.5, 13.3] and in SEER (+7.3%, 95%CI: 5.6, 9.0).ConclusionsObserved incidence, time trends and sociodemographic variations of non-WT may reflect differential registration practices and healthcare delivery patterns including differences regarding surveillance, coding and treatment practices. |
| |
| Keywords: | Non-Wilms renal tumors Childhood Incidence Time trends Age differentials |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
